Search Results

There are 33782 results for: content related to: Assurance in clinical trial design

  1. Methods for one-sided testing of the difference between proportions and sample size considerations related to non-inferiority clinical trials

    Pharmaceutical Statistics

    Volume 7, Issue 2, April/June 2008, Pages: 130–141, Rebekkah S. Dann and Gary G. Koch

    Article first published online : 25 MAY 2007, DOI: 10.1002/pst.287

  2. Type I error and power in trials with one interim futility analysis

    Pharmaceutical Statistics

    Volume 3, Issue 1, January/March 2004, Pages: 51–59, William H. Chang and Christy Chuang-Stein

    Article first published online : 2 MAR 2004, DOI: 10.1002/pst.93

  3. Partition testing in dose–response studies with multiple endpoints

    Pharmaceutical Statistics

    Volume 6, Issue 3, July/September 2007, Pages: 181–192, Yi Liu, Jason Hsu and Stephen Ruberg

    Article first published online : 25 JUL 2007, DOI: 10.1002/pst.295

  4. Using confidence intervals around individual means to assess statistical significance between two means

    Pharmaceutical Statistics

    Volume 3, Issue 3, July/September 2004, Pages: 217–222, Steven A. Julious

    Article first published online : 13 SEP 2004, DOI: 10.1002/pst.126

  5. Sample size determination in fixed-dose combination drug studies

    Pharmaceutical Statistics

    Volume 2, Issue 4, October/December 2003, Pages: 273–278, Kurex Sidik and Jeffrey N. Jonkman

    Article first published online : 5 DEC 2003, DOI: 10.1002/pst.67

  6. Sample size calculations for clinical studies allowing for uncertainty about the variance

    Pharmaceutical Statistics

    Volume 5, Issue 1, January/March 2006, Pages: 29–37, Steven A. Julious and Roger J. Owen

    Article first published online : 24 FEB 2006, DOI: 10.1002/pst.197

  7. Choice of alpha spending function and time points in clinical trials with one or two interim analyses

    Pharmaceutical Statistics

    Volume 3, Issue 3, July/September 2004, Pages: 193–203, Murray R. Selwyn and Susan M. Fish

    Article first published online : 13 SEP 2004, DOI: 10.1002/pst.108

  8. A new approach to estimating shelf-life

    Pharmaceutical Statistics

    Volume 3, Issue 1, January/March 2004, Pages: 3–11, Andreas Kiermeier, Richard G. Jarrett and Arūnas P. Verbyla

    Article first published online : 2 MAR 2004, DOI: 10.1002/pst.78

  9. Optimal design of clinical trials comparing several treatments with a control

    Pharmaceutical Statistics

    Volume 6, Issue 1, January/March 2007, Pages: 23–33, Ian C. Marschner

    Article first published online : 22 AUG 2006, DOI: 10.1002/pst.240

  10. 25 years of Bayesian methods in the pharmaceutical industry: a personal, statistical bummel

    Pharmaceutical Statistics

    Volume 6, Issue 4, October/December 2007, Pages: 261–281, Andrew P. Grieve

    Article first published online : 22 OCT 2007, DOI: 10.1002/pst.315

  11. Reproducibility of clinical data I: continuous outcomes

    Pharmaceutical Statistics

    Volume 3, Issue 2, April/June 2004, Pages: 99–108, Nicole Jill-Marie Blackman

    Article first published online : 15 JUN 2004, DOI: 10.1002/pst.104

  12. Design of clinical trials using an adaptive test statistic

    Pharmaceutical Statistics

    Volume 1, Issue 2, December 2002, Pages: 97–105, John Lawrence

    Article first published online : 9 JAN 2003, DOI: 10.1002/pst.14

  13. Surrogate threshold effect: an alternative measure for meta-analytic surrogate endpoint validation

    Pharmaceutical Statistics

    Volume 5, Issue 3, July/September 2006, Pages: 173–186, Tomasz Burzykowski and Marc Buyse

    Article first published online : 10 MAY 2006, DOI: 10.1002/pst.207

  14. Accounting for informative non-compliance with a bivariate exponential model in the design of endpoint trials

    Pharmaceutical Statistics

    Volume 4, Issue 3, July/September 2005, Pages: 173–186, Qi Jiang, Steven Snapinn and Boris Iglewicz

    Article first published online : 1 SEP 2005, DOI: 10.1002/pst.173

  15. Repeated-measures models in the analysis of QT interval

    Pharmaceutical Statistics

    Volume 2, Issue 3, July/September 2003, Pages: 175–190, Alex Dmitrienko and Brian Smith

    Article first published online : 2 SEP 2003, DOI: 10.1002/pst.53

  16. Approaches to evaluation of treatment effect in randomized clinical trials with genomic subset

    Pharmaceutical Statistics

    Volume 6, Issue 3, July/September 2007, Pages: 227–244, Sue-Jane Wang, Robert T. O'Neill and H. M. James Hung

    Article first published online : 9 AUG 2007, DOI: 10.1002/pst.300

  17. A unifying approach to non-inferiority, equivalence and superiority tests via multiple decision processes

    Pharmaceutical Statistics

    Volume 6, Issue 3, July/September 2007, Pages: 193–203, Chihiro Hirotsu

    Article first published online : 28 AUG 2007, DOI: 10.1002/pst.305

  18. Comparison of sample size formulae for 2 × 2 cross-over designs applied to bioequivalence studies

    Pharmaceutical Statistics

    Volume 4, Issue 4, October/December 2005, Pages: 233–243, Arminda Lucia Siqueira, Anne Whitehead, Susan Todd and María M. Lucini

    Article first published online : 6 OCT 2005, DOI: 10.1002/pst.183

  19. Exploring changes in treatment effects across design stages in adaptive trials

    Pharmaceutical Statistics

    Volume 8, Issue 1, January/March 2009, Pages: 62–72, Tim Friede and Robin Henderson

    Article first published online : 31 MAR 2008, DOI: 10.1002/pst.332

  20. An application of a multi-stage strategy involving confidence intervals to evaluate whether a response rate is favourable or not

    Pharmaceutical Statistics

    Volume 3, Issue 1, January/March 2004, Pages: 25–37, Sharon C. Murray, Mary F. Otterness, John K. Forster, Diane J. Catellier and Gary G. Koch

    Article first published online : 2 MAR 2004, DOI: 10.1002/pst.89